Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Wenbin Jia *Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Clinical Trial Center, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, 16766 Jingshi Road, Jinan, 250014, Shandong Province, China. jia.wenbin.t6@dc.tohoku.ac.jp.ORCID http://orcid.org/0000-0003-2596-1898
Xuejia He *Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Yong HeDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Clinical Trial Center, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, 16766 Jingshi Road, Jinan, 250014, Shandong Province, China.ORCID http://orcid.org/0000-0002-7460-2691
Furong ZhaoDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Clinical Trial Center, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, 16766 Jingshi Road, Jinan, 250014, Shandong Province, China.
Kohji FukunagaDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-Aoba, Aoba, Sendai, 980-8578, Japan. kfukunaga@tohoku.ac.jp.ORCID http://orcid.org/0000-0001-8526-2824
Wei ZhaoDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Clinical Trial Center, Shandong Engineering and Technology Research Center for Pediatric Drug Development, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, 16766 Jingshi Road, Jinan, 250014, Shandong Province, China. zhao4wei2@hotmail.com.ORCID http://orcid.org/0000-0002-1830-338X
Funding
National Natural Science Foundation of China 82504767Natural Science Foundation of Shandong Province ZR2025QC2056ZTaishan Scholars Program for Young Experts of Shandong Province tsqnz20250771
6 · The paper itself
Abstract
Drug addiction is a serious brain disorder with widespread somatic, psychological, psychiatric, and legal consequences, characterized by compulsive drug seeking, craving, withdrawal, and relapse, particularly with psychostimulants. A key feature of drugs commonly abused by humans is their ability to enhance dopamine (DA) neurotransmission in mesolimbic circuits, thereby activating DA receptors and altering emotional and motivational behaviors. Recent studies have demonstrated that dopamine D2 receptors (D2Rs), existing both as monomers and as D1/D2 receptor heteromers with dopamine D1 receptors (D1Rs), are critically involved in the neurobiological mechanisms underlying drug addiction. Furthermore, Ca
Indexed as
Calcium-Calmodulin-Dependent Protein Kinase Type 2Protein MultimerizationReceptors, Dopamine D1Receptors, Dopamine D2Signal TransductionSubstance-Related DisordersAnimalsHumansCalcium-Calmodulin-Dependent Protein Kinase Type 2Receptors, Dopamine D1Receptors, Dopamine D2Ca2+/calmodulin-dependent protein kinase IID1/D2 receptor heteromersDopamine D2 receptorsDrug addictionFatty acid-binding protein 3
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dopamine D2 Receptors, D1/D2 Receptor Heteromers and CaMKII Signaling in the Neurobiology of Drug Addiction. · full record | OpenQuestion